References

Alexander, Bruce K. The Globalization of Addiction: A Study in Poverty of the Spirit. Oxford University Press. 2010.

Alper, Kenneth R., Howard S. Lotsof, Feerte M. N. Frenken, Daniel J. Luciano, Jan Bastiaans. Treatment of Acute Opioid Withdrawal with Ibogaine. The American Journal on Addictions, 1999.

Alper KR, Glick SD, Cordell GA, editors. Ibogaine: Proceedings of the First International Conference. San Diego; Academic Press, pp 1-38. 2001.

Alper, Kenneth R, Lotsof, Howard S., Kaplan, Charles D. The ibogaine medical subculture. Journal of Ethnopharmacology. August, 2007.

Alper, Kenneth R, Marina Stajic, and James R. Gill. Fatalities Temporally Associated with the Ingestion of Ibogaine. Journal of Forensic Sciences. March 2012.

Alper, Kenneth, Rong Bai, Nian Liu, Steven J. Fowler, Xi-Ping Huang, Silvia G. Priori, Yanfei Ruan. hERG Blockade by Iboga Alkaloids. Cardiovascular Toxicology. January 2015.

Bonny, Helen L., Walter Panke. The Use of Music in Psychedelic (LSD) Psychotherapy. Journal of Music Therapy. 1972.

Brown, Thomas Kingsley. Ibogaine in the Treatment of Substance Dependence. Current Drug Abuse Reviews. 2013.

Busjahn A, Seebohm G, Maier G, Toliat MR, Nürnberg P, Aydin A, Luft FC, Lang F. Association of the serum and glucocorticoid regulated kinase (sgk1) gene with QT interval. Cellular Physiology and Biochemistry. 2004.

Carnicella, S, He DY, Yowell QV, Glick SD, Ron D. Noribogaine, but not 18-MC, exhibits similar actions as ibogaine on GDNF expression and ethanol self-administration. Addiction Biology, October 2010.

Dyer, C. Doctor is suspended for prescribing a drug for pornography “addiction“ without giving the risks. BMJ. 2011.
Ghuran, Azad, and Jim Nolan. The cardiac complications of recreational drug use. West J Med. December 2000.

The Global Ibogaine Therapy Alliance (GITA). Event Summary: 4th International Ibogaine Therapy Provider’s Conference. Durban, South Africa. May 19, 2014

Glue P, Winter H, Garbe K, Jakobi H, Lyudin A, Lenagh-Glue Z, Hung CT. Influence of CYP2D6 activity on the pharmacokinetics and pharmacodynamics of a single 20 mg dose of ibogaine in healthy volunteers. Journal of Clinical Pharmacology. Feb 4, 2015.

Goutarel, R., Gollnhofer, O., and Sillans, R. “Pharmacodynamics and Therapeutic Actions of Iboga and Ibogaine”. Psychedelic Monographs and Essays. 1993.

Grof, S. and Grof, C. (eds.). Spiritual Emergency: When Personal Transformation Becomes a Crisis. Los Angeles, CA. J. P. Tarcher. 1989.

Grof, S (with H.Z. Bennett). The Holotropic Mind. Harper, San Francisco, 1992.

Grof, S. The Thirst for Wholeness: Attachment, Addiction, and the Spiritual Path. Harper, San Francisco, 1993.

Grof, S. Spiritual Emergencies: Understanding and Treatment of Psychospiritual Crises. Reality Sandwhich. September 19, 2008.

Haning W, Goebert D. Electrocardiographic abnormalities in methamphetamine abusers. Addiction. April 2007.

Härtter, Sebastian, et al. Effects of caffeine intake on the pharmacokinetics of melatonin, a probe drug for CYP1A2 activity. British Journal of Clinical Pharmacology. December 2003.

He DY, Ron D. Autoregulation of glial cell line-derived neurotrophic factor expression: implications for the long-lasting actions of the anti-addiction drug, Ibogaine. FASEB Journal, November 2006.

Hofmann, Stefan G., Anu Asnaani, Imke J.J. Vonk, Alice T. Sawyer, Angela Fang. The Efficacy of Cognitive Behavioral Therapy: A Review of Meta-analyses. Cognit Ther Res. October, 2012.

Houenou J, Homri W, Leboyer M, et al. Ibogaine-associated psychosis in schizophrenia: A case report. Journal of Clinical Psychopharmacology. 2011.

Johnson MW, Richards WA, Griffiths RR. Human hallucinogen research: guidelines for safety. J Psychopharmacol. 1 July 2008.

Karle CA, Kiehn J. An ion channel ‘addicted’ to ether, alcohol and cocaine: the HERG potassium channel. Cardiovascular research. January 2002.

Koenig, Xaver, and Karlheinz Hilber. The Anti-Addiction Drug Ibogaine and the Heart: A Delicate Relation. Molecules. 2015.

Kornick CA, Kilborn MJ, Santiago-Palma J, Schulman G, Thaler HT, Keefe DL, Katchman AN, Pezzullo JC, Ebert SN, Woosley RL, Payne R, Manfredi PL. QTc interval prolongation associated with intravenous methadone. Pain. October 2003.

Leary, Timoth, Richard Alpert, and Ralph Metzner. The Psychedelic Experience: A Manual Based on the Tibetan Book of the Dead. Citadel Press, 1964.

Litjens, Rudd P.W., Tibor M. Brunt. How toxic is ibogaine? Clinical Toxicology. 25 January, 2016.

Lotsof, Howard S. “Compositions for the treatment of hepatitis c and methods for using compositions for the treatment of hepatitis c.” US Patent Application EP 2083825 A1. September 2006.

Marion Lee, et al. A Comprehensive Review of Opioid-Induced Hyperlergeisa. Pain Physician. 2011.

Marta, Cole J., Wesley C. Ryan, Alex Kopelowicz, Ralph J. Koek. Mania Following Use of Ibogaine: A Case Series. The American Journal on Addictions. 2015.

Mass, Uwe and Suster Strubelt. “Polyrhythms supporting a pharmacotherapy: Music in the iboga initiation ceremony in Gabon.” Music and Altered states: Consciousness, Transcendence, Therapy and Addictions. Eds. David Aldridge and Jörg Fachner. Jessica Kingsley Publishers, London and Philadelphia, 2006.

Mate, Gabor. In the Realm of Hungry Ghosts: Close Encounters with Addiction. Vintage Canada. 2009.

Naranjo, C. The Healing Journey. Pantheon Books, New York, 1974.

Organisation for Economic Co-operation and Development (OECD). “Pharmaceutical consumption.” Health at a Glance 2013: OECD Indicators. OECD Publishing, 2013.

Parker, Linda A, Siegel, Shepard. Modulation of the Effects of Rewarding Drugs by Ibogaine. The Alkaloids, Vol.56. The Academic Press. 2001.

Popik, P. Facilitation of memory retrieval by the “anti-addictive” alkaloid, ibogaine. Life Science. 1996.

Popik, P, P. Skolnick. “The Alkaloids.” Ed. G.A. Cordell. p. 197. The Academic Press. 1999.

Schenberg, Eduardo Ekman, Maria Angélica de Castro Comis, Bruno Rasmussen Chaves and Dartiu Xavier da Silveira. Treating drug dependence with the aid of ibogaine: A retrospective study. Journal of Psychopharmacology. September 2014.

Szumlinski KK, Balogun MY, Maisonneuve IM, Glick SD. Interactions between iboga agents and methamphetamine sensitization: studies of locomotion and stereotypy in rats. Psychopharmacology. August 2000.

Tajima, Yutaka. Coffee-induced Hypokalaemia. Clin Med Insights Case Rep. 2010.

Ed. Tatarsky, Andrew. Harm Reduction Psychotherapy: A New Treatment for Drug and Alcohol Problems. Jason Aronson, Inc. June 2007.

Thurner, Patrick, Anna Stary-Weinzinger, Hend Gafar, Vaibhavkumar S. Gawali, Oliver Kudlacek, Juergen Zezula, Karlheinz Hilber, Stefan Boehm, Walter Sandtner, and Xaver Koenig. Mechanism of hERG Channel Block by the Psychoactive Indole Alkaloid Ibogaine. Journal of Pharmacology and Experimental Therapeutics. November 2013.

World Health Organization (WHO). Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence. 2009.

World Health Organization (WHO). “Depression: Fact sheet N°369.” October 2012.

Vieweg, W. Victor R., Mehrul Hasnain, Robert H. Howland, Thomas Clausen, Jayanthi N. Koneru, Christopher Kogut, Ericka L. Breden Crouse, Jules C. Hancox, Antony Fernandez, and Ananda K. Pandurangi. Methadone, QTc interval prolongation and torsade de pointes: Case reports offer the best understanding of this problem. Ther Adv Psychopharmacol. August 2013.

©2012-2017 Global Ibogaine Therapy Alliance - Privacy Policy - Contact Us

or

Log in with your credentials

or    

Forgot your details?

or

Create Account